Avi Weiss, MD
Urology · Las Vegas, NVNPI 1497977334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.
Across 42 payments — averaging $32.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$202
- Astellas Pharma US Inc$169
- Tolmar, Inc.$155
- Urogen Pharma, Inc.$125
- Urovant Sciences Inc$125
- Olympus America Inc.$117
- plus $467 from 12 others
What the payments were for
- Food & beverage$1,361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 6 | $202 |
| Astellas Pharma US Inc | 7 | $169 |
| Tolmar, Inc. | 5 | $155 |
| Urogen Pharma, Inc. | 1 | $125 |
| Urovant Sciences Inc | 1 | $125 |
| Olympus America Inc. | 1 | $117 |
| Johnson & Johnson(2 entities) | 4 | $101 |
| Boston Scientific | 4 | $70 |
| Novartis | 2 | $56 |
| Coloplast | 2 | $48 |
| AbbVie | 2 | $48 |
| Endo USA, Inc. | 1 | $28 |
| Teleflex LLC | 1 | $24 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$125
- JELMYTO$125
- Olympus Cysto-Resection$117
How this compares
$1,361 in reported general payments places this provider in the 30th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $567 |
| Tamsulosin Hcl | 42 | $524 |
| Finasteride | 27 | $445 |
Paid to pharmacies, not to this prescriber.
Other urology in Las Vegas
- Vijay GoliLas Vegas$105K
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Mulugeta KassahunLas Vegas$13K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.